Aceragen expects to initiate 3 clinical studies in 2022
Aceragen intends to execute clinical programs for its lead investigational products, ACG-701 and ACG-801. Please watch this site for updates on our progress toward this goal or you can contact us directly at email@example.com. Under section 561(b) of the FD&C Act, Aceragen’s medical staff and advisors will evaluate Expanded Access requests following review of Phase III clinical data. All such requests should be initiated via the designated contact form.